LUNDBECK, LLC
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- $6.8B
- Website
- http://www.lundbeck.com
An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms
- First Posted Date
- 2011-08-10
- Last Posted Date
- 2012-09-13
- Lead Sponsor
- Lundbeck LLC
- Registration Number
- NCT01413711
A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)
- First Posted Date
- 2011-01-17
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- Lundbeck LLC
- Target Recruit Count
- 65
- Registration Number
- NCT01278173
- Locations
- 🇺🇸
CNMRI, Dover, Delaware, United States
🇺🇸Peachtree Neurological Clinic, Atlanta, Georgia, United States
🇺🇸OSF Saint Francis Medical Center, Peoria, Illinois, United States
Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2018-03-21
- Lead Sponsor
- Lundbeck LLC
- Target Recruit Count
- 267
- Registration Number
- NCT01160770
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- Lundbeck LLC
- Target Recruit Count
- 108
- Registration Number
- NCT01128959
- Locations
- 🇺🇸
Leonard J. Chabert Medical Center, Houma, Louisiana, United States
🇺🇸Temple University Health systems, Philadelphia, Pennsylvania, United States
🇺🇸Clinical Trials Incorporated, Little Rock, Arkansas, United States
A Study of the Pharmacokinetics (PK) and Safety of IV Carbamazepine Relative to Oral Carbamazepine in Adults With Epilepsy
- Conditions
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2010-04-23
- Lead Sponsor
- Lundbeck LLC
- Target Recruit Count
- 98
- Registration Number
- NCT01079351
Sabril Patient Registry
- Conditions
- Interventions
- First Posted Date
- 2010-02-23
- Last Posted Date
- 2016-07-29
- Lead Sponsor
- Lundbeck LLC
- Target Recruit Count
- 9423
- Registration Number
- NCT01073579
Clobazam in Patients With Lennox-Gastaut Syndrome
- Conditions
- Interventions
- First Posted Date
- 2007-08-21
- Last Posted Date
- 2012-02-09
- Lead Sponsor
- Lundbeck LLC
- Target Recruit Count
- 238
- Registration Number
- NCT00518713
- Locations
- 🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States
🇺🇸Baylor College of Medicine Pediatric Neurology, Houston, Texas, United States
🇺🇸Jefferson Epilepsy Center, Philadelphia, Pennsylvania, United States
Clobazam in Subjects With Lennox-Gastaut Syndrome
- Conditions
- Interventions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2012-02-09
- Lead Sponsor
- Lundbeck LLC
- Target Recruit Count
- 68
- Registration Number
- NCT00162981
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Tennessee Health Science Center, Memphis, Tennessee, United States
🇺🇸Dallas Pediatric Neurology Associates, Dallas, Texas, United States
Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2005-07-29
- Last Posted Date
- 2011-06-17
- Lead Sponsor
- Lundbeck LLC
- Target Recruit Count
- 90
- Registration Number
- NCT00125138
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸University of South Florida, Tampa, Florida, United States
🇺🇸Northwest Neurospecialists, PLLC, Tucson, Arizona, United States